Stockscreener 앱 받기
6.115
1.93%
-0.115
전일 마감가:
$6.23
열려 있는:
$6.23
하루 거래량:
103.20K
Relative Volume:
0.90
시가총액:
$172.27M
수익:
$21.25M
순이익/손실:
$-16.05M
주가수익비율:
-6.115
EPS:
-1
순현금흐름:
$-17.14M
1주 성능:
+1.66%
1개월 성능:
+31.40%
6개월 성능:
-8.53%
1년 성능:
-33.51%
1일 변동 폭
$5.79
$6.43
1주일 범위
$5.79
$6.46
52주 변동 폭
$3.96
$11.92
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
명칭
Fennec Pharmaceuticals Inc
전화
(919) 636-4530
주소
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
FENC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
6.125 | 172.27M | 21.25M | -16.05M | -17.14M | -0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.00 | 117.11B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.96 | 82.10B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
618.98 | 36.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.88 | 32.56B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.00 | 27.71B | 3.30B | -501.07M | 1.03B | -2.1146 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-11-22 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-09-07 | 개시 | CapitalOne | Overweight |
| 2022-08-08 | 재개 | Craig Hallum | Buy |
| 2020-06-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-10-11 | 개시 | Goldman | Buy |
Fennec Pharmaceuticals Inc 주식(FENC)의 최신 뉴스
Fennec Pharmaceuticals director sells $39,351 in shares By Investing.com - Investing.com Canada
Fennec Pharmaceuticals director sells $39,351 in shares - Investing.com India
Long Term Trading Analysis for (FENC) - Stock Traders Daily
A Data-Based Look At Fennec Pharmaceuticals Inc (FENC) - Stocks Register
Improved Revenues Required Before Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Stock's 25% Jump Looks Justified - Simply Wall St
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2024 - Marketscreener.com
Fennec Pharmaceuticals (NASDAQ:FENC) Upgraded at Stephens - Defense World
Fennec Pharmaceuticals (TSE:FRX) Upgraded at Stephens - Defense World
Fennec Pharmaceuticals (TSE:FRX) Upgraded by Stephens to "Strong-Buy" Rating - MarketBeat
Fennec Pharmaceuticals (NASDAQ:FENC) Upgraded by Stephens to Strong-Buy Rating - MarketBeat
Fennec Pharmaceuticals (TSE:FRX) Share Price Crosses Below 50 Day Moving AverageShould You Sell? - MarketBeat
DG Capital Management, LLC Adjusts Stake in Fennec Pharmaceutica - GuruFocus.com
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference - The Manila Times
Fennec Pharmaceuticals Drops To US$4.26, Yet Insiders May Have Sold Too Early - Simply Wall St
Fennec Pharmaceuticals Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Fennec Pharma stock hits 52-week low at $4.07 amid challenges - Investing.com Australia
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2024 Earnings Call Transcript - Insider Monkey
Wedbush Analysts Decrease Earnings Estimates for FENC - MarketBeat
What is Wedbush's Forecast for TSE:FRX FY2025 Earnings? - MarketBeat
Earnings call: Fennec Pharmaceuticals reports robust Q3 growth By Investing.com - Investing.com Australia
Earnings call: Fennec Pharmaceuticals reports robust Q3 growth - Investing.com
Wedbush Reaffirms “Outperform” Rating for Fennec Pharmaceuticals (NASDAQ:FENC) - Defense World
Fennec Pharmaceuticals Inc (FENC) Quarterly 10-Q Report - Quartzy
Fennec Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Fennec Pharma Q3 Sales Rise to $7M, Losses Widen Despite PEDMARK Reimbursement Success | FENC Stock News - StockTitan
Apogee Therapeutics (NASDAQ:APGE) and Fennec Pharmaceuticals (NASDAQ:FENC) Financial Contrast - Defense World
FENCFennec Pharmaceuticals Inc. Latest Stock News & Market Updates - StockTitan
Insider Sale: Director Rosty Raykov Sells Shares of Fennec Pharm - GuruFocus.com
Insider Selling: Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells 2,431 Shares of Stock - MarketBeat
Fennec Pharmaceuticals director Raykov Rosty sells $10,477 in stock - Investing.com India
Fennec Pharmaceuticals director Raykov Rosty sells $10,477 in stock By Investing.com - Investing.com South Africa
Fennec Pharmaceuticals (FENC) to Release Earnings on Thursday - MarketBeat
Fennec Pharmaceuticals (FRX) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 - ForexTV.com
RTP drugmaker appoints new execs following CEO swap - The Business Journals
Fennec Pharmaceuticals Strengthens Leadership Team for Growth - TipRanks
Individual investors account for 31% of Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) ownership, while hedge funds account for 30% - Yahoo Finance
Fennec Pharmaceuticals (TSE:FRX) Stock Price Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat
Eupraxia Pharmaceuticals Inc. - Baystreet.ca
Fennec Pharmaceuticals expands leadership team - The Pharma Letter
Fennec Pharmaceuticals Inc. - Baystreet.ca
Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth - The Manila Times
Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company’s Next Stage of Growth - ForexTV.com
Q3 EPS Estimates for FENC Boosted by Capital One Financial - Defense World
Capital One Financial Estimates TSE:FRX Q3 Earnings - MarketBeat
Financial Comparison: Kodiak Sciences (NASDAQ:KOD) & Fennec Pharmaceuticals (NASDAQ:FENC) - Defense World
Fennec Pharma stock hits 52-week low at $4.11 amid market challenges - Investing.com India
Fennec Pharmaceuticals director sells shares worth over $6,000 By Investing.com - Investing.com South Africa
Fennec Pharmaceuticals Inc (FENC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Fennec Pharmaceuticals Inc 주식 (FENC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RALLIS CHRIS A | Director |
Dec 02 '24 |
Option Exercise |
2.69 |
10,000 |
26,900 |
58,623 |
| RALLIS CHRIS A | Director |
Dec 02 '24 |
Sale |
6.14 |
6,409 |
39,351 |
52,214 |
0.35%
2.61%
자본화:
|
볼륨(24시간):